All
Targeted Treatments Dominate Spending Landscape in Oncology
May 21st 2015A study published in the Journal of Clinical Oncology, May 18, 2015, details payer cost and use, as well as out-of-pocket (OOP) spending, for privately insured nonelderly patients receiving oral or intravenous (IV) chemotherapy for the treatment of cancer.
Future of Breast Cancer Brings Evolving Paradigms in Treatments
May 19th 2015Joyce A. O’Shaughnessy, MD, chair, breast cancer service at Baylor-Sammons Cancer Center provided Targeted Oncology with a sneak peek into some of the recent advances in breast cancer that will be discussed at the 14th Annual International Congress on the Future of Breast Cancer®
Trastuzumab Superior to Lapatinib in Frontline HER2-Positive Metastatic Breast Cancer
May 11th 2015Treatment with lapatinib plus a taxane was associated with a shorter duration of progression-free survival compared with trastuzumab plus a taxane as a frontline therapy for patients with HER2-positive metastatic breast cancer.
Bcl-2 Inhibitor Venetoclax Granted Breakthrough Therapy Designation for CLL
May 8th 2015Venetoclax (GDC-0199/ABT-199), a Bcl-2 inhibitor, has been granted a breakthrough therapy designation by the FDA for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The designation is specific to those patients who harbor a 17p deletion (del[17p]).
NeoALTTO TIL Analysis Shows EFS, OS Association in HER2+ Breast Cancer
May 7th 2015The level of TILs identified at the time of diagnosis were found to be an independent prognostic marker for pathologic complete response and event-free survival in patients treated with neoadjuvant HER2-target therapy plus chemotherapy for HER2-positive early breast cancer.
Responses Shown in Olaparib Plus BKM120 for Ovarian and Breast Cancers
May 5th 2015The oral combination of olaparib, a PARP inhibitor, and BKM120, a PI3K inhibitor, demonstrated to be safe and clinical beneficial in women with high-grade serous ovarian cancer, as well as patients with triple-negative breast cancer.
Expert Says Olaparib Label Needs Expansion
May 5th 2015The FDA’s recent approval of olaparib for women with BRCA-mutated advanced ovarian cancer marks a significant therapeutic advance for women with the malignancy, but the specific indication is far too restrictive and the drug should be offered to many more patients.
Frontline Nivolumab Granted FDA Priority Review in Melanoma
April 30th 2015The PD-1 inhibitor nivolumab (Opdivo) has been has been assigned priority review designation from the US Food and Drug Administration (FDA) as a treatment for previously untreated patients with unresectable or metastatic melanoma.
T-VEC for Melanoma Receives FDA Panel Support
April 30th 2015Members of the FDA’s Oncologic Drugs Advisory Committee (ODAC) and Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) voted 22-1 in a combined decision to recommend approval of the oncolytic immunotherapy talimogene laherparepvec (T-VEC) as a treatment for patients with advanced melanoma.
Combining Ofatumumab With Chemotherapy Delays Progression in CLL
April 29th 2015Topline findings from the phase III COMPLEMENT 2 study indicated that treatment with ofatumumab (Arzerra) plus fludarabine and cyclophosphamide significantly improved progression-free survival (PFS) compared with fludarabine and cyclophosphamide alone in patients with relapsed chronic lymphocytic leukemia (CLL).
Liquid Biopsies Detect Minimal Residual Disease in Colorectal Cancer
April 29th 2015Two different types of liquid biopsies—plasma and urine—can detect the number of copies of the KRAS mutation in circulating DNA in patients with colorectal cancer who have resectable liver metastases with near 100% concordance with tissue biopsies, according to a pilot study presented at the 2015 Annual Meeting of the American Association for Cancer Research (AACR).
NDA Submitted for MM-398 With 5-FU and Leucovorin in Advanced Pancreatic Cancer
April 28th 2015Following the FDA fast track designation in November 2014, Merrimack Pharmaceuticals and Baxter International have completed the submission of a new drug application for MM-398 in combination with 5-fluorouracil and leucovorin, according to a statement from the drug's developers.
New Collaboration Forms for Immunotherapy Regimens in Hematologic Malignancies
April 27th 2015MedImmune Limited, a subsidiary of AstraZeneca PLC, and Celgene International II Sà rl, a subsidiary of Celgene Corporation, have formed a strategic collaboration for the development and commercialization of AstraZeneca’s anti-programmed cell death-ligand 1 (PD-L1) agent MEDI4736.